ArticleAllergy2026
Peanut Component-Specific IgE and IgG4 Are Modulated by Sublingual Immunotherapy and Are Associated With Remission in 1-4-Year-Old Children.
Article in Allergy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Immunization with Virus-Like Particles Displaying Ara h 2‑Derived Peptides to Mitigate Peanut Allergy.ACS nano medicine · 2026Article
- Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundThe safety and efficacy of 36-month peanut sublingual immunotherapy (SLIT) was recently demonstrated in peanut-allergic children (1-4 years old), with high remission rates three months post-treatment.
methodsWe performed a post hoc analysis of longitudinal changes in peanut component-specific IgE (PnC-sIgE) and IgG4 (PnC-sIgG4) levels in 1-4 year olds who underwent peanut SLIT to uncover immune mechanisms and potential biomarkers of remission. Plasma from 30 participants was analyzed at 0, 12, 24, 36, and 39 months using ImmunoCAP250 for PnC-sIgE and PnC-sIgG4 to Ara h 1, Ara h 2, Ara h 3, and Ara h 6 (Ah1-6). Mixed-effects models assessed longitudinal antibody changes, Wilcoxon tests compared antibody levels by remission status, and correlations evaluated age and baseline antibody levels.
resultsPeanut SLIT reduced IgE levels while increasing IgG4 levels specific to Pn and Ah1-6 over 36 months. No changes in sIgE were observed in the placebo group, whereas increases in Pn-, Ah1-, and Ah3-sIgG4 were noted. Participants achieving remission had lower IgE and IgG4 to Pn and Ah1-6 at baseline and throughout 36 months of SLIT. Ah2-sIgG4 showed no overlap between outcome groups at baseline, suggesting potential as a biomarker. Children under 3 had lower baseline Ah6-sIgE and Ah1-, Ah2-, and Ah6-sIgG4 levels and higher remission rates than those 3 and older, linking age, remission, and antibody profiles.
conclusionComponent-resolved analysis offers key insights into the immunological mechanisms in young children undergoing peanut SLIT, revealing lower baseline levels of Ah2-sIgG4 as a potential biomarker of remission.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.